[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Journal Information::
Articles archive::
Publication Ethics::
Peer Review Process::
Indexing Databases::
For Authors::
For Reviewers::
Contact us::
Site Facilities::
Google Scholar Metrics

Citation Indices from GS

AllSince 2019

Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
Registered in



:: Volume 30, Issue 5 (12-2022) ::
Journal of Ilam University of Medical Sciences 2022, 30(5): 68-77 Back to browse issues page
Effect of Finasteride on PSA and Histopathological Results in Patients Undergoing Prostate Biopsy
Saman Farshid1 , Ali Tehranchi1 , Amir Jamei2 , Faramarz Ojaghi3 , Farid Kalashipour * 4
1- Dept of Urology, Imam Khomeini Hospital, Urmia, Urmia University of Medical Sciences, Urmia,
2- Dept of Urology, Imam Khomeini Hospital, Urmia, Urmia University of Medical Sciences, Urmia, Iran
3- Dept of Operating Room, Imam Khomeini Hospital Urmia, Urmia University of Medical Sciences, Urmia, Iran
4- Dept of Operating Room, Faculty of Nursing and Midwifery, Kurdistan University of Medical Sciences, Sanandaj, Iran , faridkalashi871@gmail.com
Abstract:   (1739 Views)
Introduction: Prostate cancer management focuses on rapid diagnosis and treatment. The present study was performed to investigate the effect of finasteride on PSA changes and biopsy results.
Material & Methods: This retrospective descriptive-analytical study included 98 patients between the ages of 50 and 75 years with PSA levels between 2.5 and 10 and negative DRE candidates for prostate biopsy. Patients were divided into two groups. The first group consisted of patients who consented to a prostate biopsy based on PSA levels. The second group of patients did not consent to prostate biopsy during referral. Moreover, they tended to delay prostate biopsy. At the end of the three-month period, patients who agreed to prostate biopsy were sampled. The effect of treatment on biopsy results and changes in PSA levels were compared between the two groups.
(Ethic code: IR.UMSU.REC.1396.20)
Findings: Three months after the initiation of the study, the mean PSA level was 3.43±6.11 ng/ml in the case group and 7.36±2.20 in the control group. This difference was statistically significant (P=0.031). After three months of finasteride, the mean total PSA level among those who tested positive for biopsy was 2.41±7.63 ng/ml and among those who tested negative for biopsy was 2.98±6.42 ng/ml. This difference was also statistically significant (P=0.046).
Discussion & Conclusion: The use of finasteride in patients suspected of having prostate cancer for at least three months can lead to a correct decision regarding prostate biopsy and reduce the number of negative prostate cancer results in the biopsy, as well as the burden on the treatment system to use improper prostate biopsy.
Keywords: BPH, Finasteride, Prostate Biopsy, Prostate Cancer, Prostate-specific antigen
Full-Text [PDF 947 kb]   (1168 Downloads)    
Type of Study: Research | Subject: General
Received: 2021/10/25 | Accepted: 2022/06/14 | Published: 2022/12/6
1. Doll R, Muir C, Waterhouse J. Cancer Incidence in Five Continents: Volume II–1970. Springer 2012. doi:10.1007/978-3-642-85851-2
2. Pernar CH, Ebot EM, Wilson KM, Mucci LA. The epidemiology of prostate cancer. Cold Spring Harb Perspect Med 2018;8:a030361. doi: 10.1101/cshperspect.a030361
3. Brawley OW. Prostate cancer epidemiology in the United States. World J Urol 2012;30:195-200. doi: 10.1007/s00345-012-0824-2.
4. Asimakopoulos AD, Fraga CT, Annino F, Pasqualetti P, Calado AA, Mugnier C. Randomized comparison between laparoscopic and robot-assisted nerve-sparing radical prostatectomy. J Sex Med 2011;8:1503-12. doi: 10.1111/j.1743-6109.2011.02215.x.
5. Lilja H, Cronin AM, Dahlin A, Manjer J, Nilsson PM, Eastham JA, et al. Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate‐specific antigen at or before age 50. Cancer 2011;117:1210-9. doi: 10.1002/ cncr.25568.
6. Ko JS, Landis P, Carter HB, Partin AW. Effect of intra‐observer variation in prostate volume measurement on prostate‐specific antigen density calculations among prostate cancer active surveillance participants. BJU Int 2011;108:1739-42. doi: 10.1111/j.1464-410X. 2011.10223.x
7. Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH,et al. A multicenter study of [-2] pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J urol 2011;185:1650-5. doi: 10.1016/j. juro.2010.12.032.
8. Sarwar S, Adil MA, Nyamath P, Ishaq M. Biomarkers of prostatic cancer: an attempt to categorize patients into prostatic carcinoma, benign prostatic hyperplasia, or prostatitis based on serum prostate specific antigen, prostatic acid phosphatase, calcium, and phosphorus. Prostate Cancer 2017;2017:5687212. doi: 10.1155/2017/ 5687212.
9. Zahnd WE, Jenkins WD, Mueller-Luckey GS. Cancer mortality in the Mississippi delta region: descriptive epidemiology and needed future research and interventions. J Health Care Poor Underserved 2017;28:315-28. doi: 10.1353/hpu.2017.0025.
10. Djulbegovic M, Beyth RJ, Neuberger MM, Stoffs TL, Vieweg J, Djulbegovic B, et al. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. Bmj 2010;341. doi: 10.1136/bmj.c4543.
11. Crawford ED, Rove KO, Trabulsi EJ, Qian J, Drewnowska KP, Kaminetsky JC, et al. Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases. J urol 2012;188:1726-31. doi: 10.1016/j.juro.2012.07.023.
12. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24. doi: 10.1056/NEJMoa030660.
13. Hsing AW, Reichardt JK, Stanczyk FZ. Hormones and prostate cancer: current perspectives and future directions. Prostate 2002;52:213-35. doi: 10.1002/pros.10108.
14. Cheng I, Chen GK, Nakagawa H, He J, Wan P, Laurie CC, et al. Evaluating Genetic Risk for Prostate Cancer among Japanese and LatinosGWAS of Prostate Cancer in Japanese and Latinos. ancer Epidemiol Biomarkers Prev 2012;21:2048-58. doi: 10.1158/1055-9965.EPI-12-0598.
15. Sun JH, Lee SA. Association between CAG repeat polymorphisms and the risk of prostate cancer: a meta-analysis by race, study design and the number of (CAG) n repeat polymorphisms. Int J Mol Med 2013;32:1195-203. doi: 10.3892/ijmm.2013.1474.
16. Djavan BO, Zlotta A, Remzi M, Ghawidel K, Basharkhah AL, Schulman CC, et al. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. J Urol 2000;163:1144-9.
17. Etzioni RD, Howlader N, Shaw PA, Ankerst DP, Penson DF, Goodman PJ, et al. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol 2005;174:877-81. doi: 10.1097/01.ju.0000169255.64518.fb.
18. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010;362:1192-202. doi: 10.1056/NEJMoa0908127.
19. Andriole GL, Bostwick D, Brawley OW, Gomella L, Marberger M, et al. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. J Urol 2011;185:126-31. doi: 10.1016/j.juro.2010.09.011.
20. Roehrborn CG, Andriole GL, Wilson TH, Castro R, Rittmaster RS. Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial. Eur Urol 2011;59:244-9. doi: 10.1016/j. eururo.2010.10.040.
21. Parsons JK, Schenk JM, Arnold KB, Messer K, Till C, Thompson IM, et al . Finasteride reduces the risk of incident clinical benign prostatic hyperplasia. Eur Urol 2012;62:234-41. doi: 10.1016/j.eururo.2012.03.007.
22. Liang JA, Sun LM, Lin MC, Chang SN, Sung FC, Muo CH, et al. A population-based nested case-control study in Taiwan: use of 5α-reductase inhibitors did not decrease prostate cancer risk in patients with benign prostate hyperplasia. Oncologist 2012;17:986-91. doi: 10.1634/theoncologist.2011-0464.
23. Moroz A, Delella FK, Almeida R, Lacorte LM, Favaro WJ, Deffune E, et al. Finasteride inhibits human prostate cancer cell invasion through MMP2 and MMP9 downregulation. PLoS One 2013 ;8:e84757. doi: 10.1371/ journal.pone.0084757.
24. Nickel JC, Gilling P, Tammela TL, Morrill B, Wilson TH, Rittmaster RS. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int 2011;108:388-94. doi: 10.1111/j.1464-410X.2011.10195.x.
25. Fryczkowski M, Bryniarski P, Szczкbara M, Paradysz A. The impact of 5-alpha reductase inhibitor vs. alpha-1 adrenergic receptor antagonists on course of prostate premalignant conditions. Adv Clin Exp Med 2014;23:79-84. doi: 10.17219/acem/37025.
26. Hoque A, Yao S, Till C, Kristal AR, Goodman PJ, Hsing AW, et al. Effect of finasteride on serum androstenedione and risk of prostate cancer within the prostate cancer prevention trial: differential effect on high-and low-grade disease. Urology 2015;85:616-20. doi: 10.1016/j.urology.2014.11.024.
27. Sane S, Mahdkhah A, Golabi P, Hesami SA, Kazemi haki B. Comparison the effect of bupivacaine plus magnesium sulfate with ropivacaine plus magnesium sulfate infiltration on postoperative pain in patients undergoing lumbar laminectomy with general anesthesia. Br J Neurosurg 2020;1-4. doi: 10.1080/ 02688697.2020.1861430
28. Haki BK, Golabi P, Lebadi S, Kalashipor F, Hamze S, Goljabini S, et al. Characterization and Identification of Mistakes and Errors Made by Clinic Staffs During Cardio Pulmonary Resuscitation. Jentashapir J Health Res 2018;9. doi:10.5812/jjhr.67162
Send email to the article author

Add your comments about this article
Your username or Email:


Ethics code: IR.UMSU.REC.1396.20

XML   Persian Abstract   Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Farshid S, Tehranchi A, Jamei A, Ojaghi F, Kalashipour F. Effect of Finasteride on PSA and Histopathological Results in Patients Undergoing Prostate Biopsy. J. Ilam Uni. Med. Sci. 2022; 30 (5) :68-77
URL: http://sjimu.medilam.ac.ir/article-1-7326-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 30, Issue 5 (12-2022) Back to browse issues page
مجله دانشگاه علوم پزشکی ایلام Journal of Ilam University of Medical Sciences
Persian site map - English site map - Created in 0.16 seconds with 41 queries by YEKTAWEB 4654